# Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

> **NCT07712588** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Dizal Pharmaceuticals** · enrollment: 880 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** Birelentinib
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamid
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07712588
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2031-01
- **Final completion:** 2032-02
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712588, "Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*